^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    neoantigen peptide vaccine

    i
    Associations
    News

    Trials

    Company:
    Mayo Clinic, National Cancer Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) (NCT05269381)
    Phase 1/2
    Mayo Clinic
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    03/31/2022
    Primary completion :
    02/24/2025
    Completion :
    02/24/2026
    KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK
    |
    TMB-H
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine